Cantor Fitzgerald analyst Alethia Young raised her price target for Tesaro (TSRO) to $68 saying AstraZeneca's (AZN) presented the Solo1 study using olaparib as a first-line treatment for BRCA ovarian cancer patients is positive for Tesaro's first-line study Prima study, with data expected in the second half of 2019. AstraZeneca's data clearly support broad use in first-line "at least" for BRCA ovarian cancer patients, which is positive for the PARP inhibitor class, Young tells investors in a research note. The analyst increased PARP inhibitor penetration in the BRCA patient at peak to 75% from 65% and reiterates an Overweight rating on Tesaro.